English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 903718      Online Users : 526
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version


    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/14183


    Title: Development of COVID-19 vaccines through augmenting antiviral immune responses: A systematic review and meta-analysis
    Authors: Ma, KSK;Lee, CC;Liu, KJ;Wang, LT
    Contributors: National Institute of Cancer Research
    Abstract: We aim to evaluate strategies on augmentation of host immunity against Severe Acute Respiratory Syndrome Coronavirus‐2 (SARS‐CoV‐2) infection. We searched clinical trials registered at the National Institutes of Health through December, 2020, and conducted analyses on inoculated population, involved immunological processes, source of injected components, and trial phases. We then searched PubMed, Embase, Scopus, and the Cochrane Central Register of Controlled Trials for their corresponding reports. A bivariate random‐ effects meta‐analysis was used to derive the pooled estimate of seroconversion and adverse events (AEs). A total of 540,269 participants were enrolled in 225 identified trials. The working mechanisms included heterologous immunity, active immunity, passive immunity, and immunotherapy. A total of 2,565 healthy adults from 10 clinical trials were included for meta‐analyses. The odd ratio (OR) was 90.82 for kinetics of serologic responses to anti‐SARS‐CoV‐2 antibody IgG titer (95% CI =36.1 – 228.49; p< 0.00001). The pooled ORs were 2.57 for solicited systemic AEs (95%CI =1.57 – 4.21; p = 0.0002), 5.72 for solicited local AEs (95% CI=2.59 – 12.67; p < 0.0001), and 2.08 for unsolicited systemic events (95% CI=1.42 – 3.05; p = 0.0002), compared to placebo or conservative treatment. Among all immune‐augmentative interventions, a paradigm shift to vaccines providing active immunity was observed. The efficacy of these interventions was promising although systemic adverse events were noted.
    Date: 2021-08
    Relation: European Journal of Immunology. 2021 Aug;51(Suppl. 1):395.
    Link to: http://dx.doi.org/10.1002/eji.202170200
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0014-2980&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000753366402130
    Appears in Collections:[劉柯俊] 會議論文/會議摘要

    Files in This Item:

    File Description SizeFormat
    ISI000753366402130.pdf222KbAdobe PDF224View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback